跳轉至內容
Merck
  • Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity.

Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity.

eLife (2019-11-05)
Rachel A Battaglia, Adriana S Beltran, Samed Delic, Raluca Dumitru, Jasmine A Robinson, Parijat Kabiraj, Laura E Herring, Victoria J Madden, Namritha Ravinder, Erik Willems, Rhonda A Newman, Roy A Quinlan, James E Goldman, Ming-Der Perng, Masaki Inagaki, Natasha T Snider
摘要

Alexander disease (AxD) is a fatal neurodegenerative disorder caused by mutations in glial fibrillary acidic protein (GFAP), which supports the structural integrity of astrocytes. Over 70 GFAP missense mutations cause AxD, but the mechanism linking different mutations to disease-relevant phenotypes remains unknown. We used AxD patient brain tissue and induced pluripotent stem cell (iPSC)-derived astrocytes to investigate the hypothesis that AxD-causing mutations perturb key post-translational modifications (PTMs) on GFAP. Our findings reveal selective phosphorylation of GFAP-Ser13 in patients who died young, independently of the mutation they carried. AxD iPSC-astrocytes accumulated pSer13-GFAP in cytoplasmic aggregates within deep nuclear invaginations, resembling the hallmark Rosenthal fibers observed in vivo. Ser13 phosphorylation facilitated GFAP aggregation and was associated with increased GFAP proteolysis by caspase-6. Furthermore, caspase-6 was selectively expressed in young AxD patients, and correlated with the presence of cleaved GFAP. We reveal a novel PTM signature linking different GFAP mutations in infantile AxD.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
双酚A型环氧树脂, used as embedding medium
Sigma-Aldrich
4,5-二氨基荧光素二乙酸酯 溶液, 5 mM in DMSO, ≥97% (HPLC)